Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 1454

1.

Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic.

Fleischhacker WW, Eerdekens M, Karcher K, Remington G, Llorca PM, Chrzanowski W, Martin S, Gefvert O.

J Clin Psychiatry. 2003 Oct;64(10):1250-7.

PMID:
14658976
3.

Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.

Emsley R, Oosthuizen P, Koen L, Niehaus DJ, Medori R, Rabinowitz J.

Clin Ther. 2008 Dec;30(12):2378-86. doi: 10.1016/j.clinthera.2008.12.020.

PMID:
19167596
4.

[Long-acting injectable risperidone: naturalistic study in three hospitals in Aquitaine].

Raignoux C, Dusouchet T, Bret P, Queuille E, Biscay ML, Caron J, Bret MC.

Encephale. 2007 Dec;33(6):973-81. doi: 10.1016/j.encep.2006.07.003. Epub 2007 Sep 4. French.

PMID:
18789790
5.

Long-term treatment of chronic schizophrenia with risperidone: an open-label, multicenter study of 386 patients.

Möller HJ, Gagiano CA, Addington DE, Von Knorring L, Torres-Plank JF, Gaussares C.

Int Clin Psychopharmacol. 1998 May;13(3):99-106.

PMID:
9690975
6.

Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets.

Chue P, Eerdekens M, Augustyns I, Lachaux B, Molcan P, Eriksson L, Pretorius H, David AS.

Eur Neuropsychopharmacol. 2005 Jan;15(1):111-7.

PMID:
15572280
7.

Efficacy and safety of long-acting risperidone in elderly patients with schizophrenia and schizoaffective disorder.

Lasser RA, Bossie CA, Zhu Y, Gharabawi G, Eerdekens M, Davidson M.

Int J Geriatr Psychiatry. 2004 Sep;19(9):898-905.

PMID:
15352149
8.

Switching stable patients with schizophrenia from depot and oral antipsychotics to long-acting injectable risperidone: reasons for switching and safety.

Hawley C, Turner M, Latif MA, Curtis V, Saleem PT, Wilton K.

Hum Psychopharmacol. 2010 Jan;25(1):37-46. doi: 10.1002/hup.1085.

PMID:
20041474
9.

Pharmacokinetics and efficacy of a direct switch from conventional depot to risperidone long-acting injection in Chinese patients with schizophrenic and schizoaffective disorders.

Lai YC, Huang MC, Chen CH, Tsai CJ, Pan CH, Chiu CC.

Psychiatry Clin Neurosci. 2009 Aug;63(4):440-8. doi: 10.1111/j.1440-1819.2009.01977.x. Epub 2009 Apr 27.

10.

Efficacy and safety of long-acting risperidone in stable patients with schizoaffective disorder.

Lasser R, Bossie CA, Gharabawi G, Eerdekens M, Nasrallah HA.

J Affect Disord. 2004 Dec;83(2-3):263-75.

PMID:
15555724
11.

Clinical experience with the long-acting injectable formulation of the atypical antipsychotic, risperidone.

Martin SD, Libretto SE, Pratt DJ, Brewin JS, Huq ZU, Saleh BT.

Curr Med Res Opin. 2003;19(4):298-305.

PMID:
12841922
12.

Long-acting risperidone in young adults with early schizophrenia or schizoaffective illness.

Lasser RA, Bossie CA, Zhu Y, Locklear JC, Kane JM.

Ann Clin Psychiatry. 2007 Apr-Jun;19(2):65-71.

PMID:
17612845
13.

A long-term, multicenter, open-label study of risperidone in elderly patients with psychosis. On behalf of the Risperidone Working Group.

Davidson M, Harvey PD, Vervarcke J, Gagiano CA, De Hooge JD, Bray G, Dose M, Barak Y, Haushofer M.

Int J Geriatr Psychiatry. 2000 Jun;15(6):506-14.

PMID:
10861916
14.

Switching to long-acting injectable risperidone is beneficial with regard to clinical outcomes, regardless of previous conventional medication in patients with schizophrenia.

Marinis TD, Saleem PT, Glue P, Arnoldussen WJ, Teijeiro R, Lex A, Latif MA, Medori R.

Pharmacopsychiatry. 2007 Nov;40(6):257-63.

PMID:
18030649
15.

Efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapies.

Möller HJ, Llorca PM, Sacchetti E, Martin SD, Medori R, Parellada E; StoRMi Study Group.

Int Clin Psychopharmacol. 2005 May;20(3):121-30.

PMID:
15812261
16.

Remission in schizophrenia: one-year Italian prospective study of risperidone long-acting injectable (RLAI) in patients with schizophrenia or schizoaffective disorder.

Rossi A, Bagalà A, Del Curatolo V, Scapati F, Bernareggi MM, Giustra MG; Risperidone Long-Acting Trial Investigators (R-LAI).

Hum Psychopharmacol. 2009 Oct;24(7):574-83. doi: 10.1002/hup.1067.

PMID:
19790173
17.

Patients in the early phases of schizophrenia and schizoaffective disorders effectively treated with risperidone long-acting injectable.

Parellada E, Andrezina R, Milanova V, Glue P, Masiak M, Turner MS, Medori R, Gaebel W.

J Psychopharmacol. 2005 Sep;19(5 Suppl):5-14.

PMID:
16144781
18.

Long-term safety and efficacy of long-acting risperidone in elderly psychotic patients.

Kissling W, Glue P, Medori R, Simpson S.

Hum Psychopharmacol. 2007 Dec;22(8):505-13.

PMID:
17902187
19.

Long-acting risperidone improves negative symptoms in stable psychotic patients.

Curtis VA, Katsafouros K, Möller HJ, Medori R, Sacchetti E.

J Psychopharmacol. 2008 May;22(3):254-61. doi: 10.1177/0269881107082119.

PMID:
18308804
20.

A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia.

Li H, Rui Q, Ning X, Xu H, Gu N.

Prog Neuropsychopharmacol Biol Psychiatry. 2011 Jun 1;35(4):1002-8. doi: 10.1016/j.pnpbp.2011.02.001. Epub 2011 Feb 18.

PMID:
21315787

Supplemental Content

Support Center